Go to the list of all blogs
GET DAILY SIGNALS
GET DAILY SIGNALSEpizyme (EPZM) reports narrower-than-expected loss in Q4 - Zacks
Epizyme (EPZM) reports narrower-than-expected loss in Q4 - Zacks
Epizyme, Inc. incurred loss of 29 cents per share in the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of loss of 49 cents and the year-ago loss of 52 cents.
Related Ticker: EPZM
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Related Blogs
Interesting Articles
A.I. Advisor
published General Information
General Information
a developer of therapeutics for the treatment of patients with genetically defined cancers
Industry Biotechnology
Industry
Biotechnology
Address
400 Technology Square
Phone
+1 617 229-5872
Employees
250
Web
https://www.epizyme.com
Interact to see
Advertisement
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.